# An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19

> **NCT05262309** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 42 (actual)

## Conditions studied

- COVID-19 Respiratory Infection
- COVID-19 Pneumonia
- Covid19

## Interventions

- **DRUG:** Pamrevlumab

## Key facts

- **NCT ID:** NCT05262309
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-12
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262309, "An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05262309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*